title: Daily diethylcarbamazine for the treatment of Brugia malayi microfilaria carriers.
abstract: BACKGROUND
  Diethylcarbamazine is effective for the treatment of brugian filaria carriers. However, the 12-day course with a daily dose of 6 mg per kg body weight is rarely completed. The World Health Organization has indicated the need for better regimes to control filariasis.
  
  
  METHODS
  We evaluated the long term effects of three different dosage regimes of diethylcarbamazine--6, 9 and 12 mg per kg body weight--to a total of 72 mg on 93 microfilaria carriers of Brugia malayi.
  
  
  RESULTS
  All cases treated with the 6 mg daily dose showed complete clearance of microfilaria immediately after the treatment. However, at the 9 and 12 mg daily doses only 91% and 85% of cases respectively showed complete clearance. There was a close association between the daily dose and the proportion of cases developing side-effects. The mean initial microfilaria counts were significantly higher in those who had side-effects than in those who did not. An 11-month follow up showed that with the 6 mg daily dose the recurrence rate of microfilaraemia was 29% while with the 12 mg daily dose it was 67%. Four per cent of patients on a daily dose of 6 and 9 mg discontinued treatment while 21% of those on the 12 mg daily dose did so.
  
  
  CONCLUSIONS
  The 6 mg daily dose of diethylcarbamazine was the most effective and best accepted regime.
authors.affiliation: Vectrol Control Research Centre, Pondicherry, India.
authors.forename: K
authors.initials: K
authors.lastname: Krishnamoorthy
authors.forename: S
authors.initials: S
authors.lastname: Sabesan
authors.forename: K N
authors.initials: KN
authors.lastname: Panicker
authors.forename: J
authors.initials: J
authors.lastname: Prathiba
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D017178:Brugia malayi; D002353:Carrier State / Q000097:blood / Q000188:drug therapy* / Q000469:parasitology; D002648:Child; D004049:Diethylcarbamazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005368:Filariasis / Q000097:blood / Q000188:drug therapy* / Q000469:parasitology; D005500:Follow-Up Studies; D006801:Humans; D012008:Recurrence
chemical_list: D004049:Diethylcarbamazine